Patents by Inventor Thomas Boesen

Thomas Boesen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EXENDIN-4 PEPTIDE ANALOGS
    Publication number: 20230303640
    Abstract: The present invention relates to exendin-4 peptide analogues comprising an exendin-4 peptide and functional variants thereof, and one or more branched amino acid probes.
    Type: Application
    Filed: August 10, 2021
    Publication date: September 28, 2023
    Inventors: Thomas Engelbrecht Nordkild JONASSEN, Thomas BOESEN
  • POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTS
    Publication number: 20230271922
    Abstract: The present disclosure relates to crystalline forms of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium salts having high solubility. The disclosure also relates to use of said crystalline forms in medicine.
    Type: Application
    Filed: August 23, 2022
    Publication date: August 31, 2023
    Inventors: Thomas BOESEN, Thomas Engelbrecht Nordkild JONASSEN, Hayley Ann REECE, Natalie Louise KELK, Alice Jane TURNER, Ross MCLELLAN
  • PHENYL PYRROLE AMINOGUANIDINE SALTS AND FORMULATIONS
    Publication number: 20230114865
    Abstract: The disclosure relates to oral formulations for gastric delivery of a pharmaceutically acceptable salt of a phenyl pyrrole aminoguanidine compound.
    Type: Application
    Filed: December 14, 2022
    Publication date: April 13, 2023
    Inventors: Thomas BOESEN, Thomas Engelbrecht Nordkild JONASSEN, Bent HØJGAARD
  • POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTS
    Publication number: 20230002319
    Abstract: The present disclosure relates to crystalline forms of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium salts having high solubility. The disclosure also relates to use of said crystalline forms in medicine.
    Type: Application
    Filed: August 23, 2022
    Publication date: January 5, 2023
    Inventors: Thomas BOESEN, Thomas Engelbrecht Nordkild JONASSEN, Hayley Ann REECE, Natalie Louise KELK, Alice Jane TURNER, Ross MCLELLAN
  • PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S)
    Publication number: 20220133839
    Abstract: The present invention relates to peptide analogues comprising one or more branched amino acid probes and a peptide, native or variants thereof.
    Type: Application
    Filed: September 9, 2021
    Publication date: May 5, 2022
    Inventor: Thomas BOESEN
  • Peptide analogues with branched amino acid probe(s)
    Patent number: 11141455
    Abstract: The present invention relates to peptide analogues comprising one or more branched amino acid probes and a peptide, native or variants thereof.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: October 12, 2021
    Assignee: TXP Pharma GmbH
    Inventor: Thomas Boesen
  • Inhibitors of histone demethylases
    Patent number: 10221139
    Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: March 5, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
  • PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S)
    Publication number: 20190030115
    Abstract: The present invention relates to peptide analogues comprising one or more branched amino acid probes and a peptide, native or variants thereof.
    Type: Application
    Filed: March 9, 2018
    Publication date: January 31, 2019
    Inventor: Thomas BOESEN
  • Inhibitors of histone demethylases
    Patent number: 10189787
    Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: January 29, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
  • Peptide analogues with branched amino acid probe(s)
    Patent number: 9950027
    Abstract: The present invention relates to peptide analogs comprising one or more branched amino acid probes and a peptide, native or variants thereof.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: April 24, 2018
    Assignee: TXP Pharma GmbH
    Inventor: Thomas Boesen
  • Alpha- and gamma-MSH analogues
    Patent number: 9951116
    Abstract: The present invention provides peptide analogs of ?-MSH and ?-MSH, comprising the amino acid sequence of human ?-MSH or ?-MSH, or variants thereof, and having a branched amino acid probe in the N-terminal part of the peptide.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: April 24, 2018
    Assignee: TXP Pharma GmbH
    Inventor: Thomas Boesen
  • INHIBITORS OF HISTONE DEMETHYLASES
    Publication number: 20170369444
    Abstract: Compounds of the form in which Q is selected from —COOH—CH?NR12, —W, —CH2NHR13, —CH=0 and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.
    Type: Application
    Filed: March 30, 2015
    Publication date: December 28, 2017
    Inventors: Marc Labelle, Rui Zhang, Cuthbert D. Martyr, Neerja Saraswat, Thomas Boesen
  • INHIBITORS OF HISTONE DEMETHYLASES
    Publication number: 20170320827
    Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Application
    Filed: February 17, 2017
    Publication date: November 9, 2017
    Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
  • Compounds and methods for inhibiting histone demethylases
    Patent number: 9802941
    Abstract: The present application relates to compounds being of Formula (I), (II), (III), (IV), (V), (VI), (IIIa), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), and (IIIg). Compounds of Formula (I) have the structure: wherein Q, R1, R18, R19, M, A and Y are as defined herein. The compounds of the application can modulate the activity of histone demethylases (HDMEs), and can be useful for the prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, e.g., cancer.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: October 31, 2017
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Thomas Boesen, Marc Labelle, Ying Yang, Neerja Saraswat, Dastagiri Dudekula, Cyril John Cook, Ramkrishna Reddy Vakiti, Rui Zhang, Farman Ullah
  • ALPHA- AND GAMMA-MSH ANALOGUES
    Publication number: 20170174738
    Abstract: The present invention provides peptide analogues of ?-MSH and ?-MSH, comprising the amino acid sequence of human ?-MSH or ?-MSH, or variants thereof, and having a branched amino acid probe in the N-terminal part of the peptide.
    Type: Application
    Filed: October 10, 2016
    Publication date: June 22, 2017
    Inventor: Thomas Boesen
  • Inhibitors of histone demethylases
    Patent number: 9650339
    Abstract: Compounds of the form In which Q is selected from —CH?NR12, —W, —CH2NHR13, —CH?O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: May 16, 2017
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Marc Labelle, Thomas Boesen, Qasim Khan, Ramkrishna Reddy Vakiti, Utpal Sharma, Ying Yang, Mukund Mehrotra, Neerja Saraswat, Farman Ullah
  • Inhibitors of histone demethylases
    Patent number: 9611220
    Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: April 4, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
  • Inhibitors of histone demethylases
    Patent number: 9611219
    Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: April 4, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
  • Alpha-and gamma-MSH analogues
    Patent number: 9486495
    Abstract: The present invention provides peptide analogues of ?-MSH and ?-MSH, comprising the amino acid sequence of human ?-MSH or ?-MSH, or variants thereof, and having a branched amino acid probe in the N-terminal part of the peptide.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: November 8, 2016
    Assignee: TXP Pharma GmbH
    Inventor: Thomas Boesen
  • INHIBITORS OF HISTONE DEMETHYLASES
    Publication number: 20160237037
    Abstract: Compounds of the form In which Q is selected from —CH?NR12, —W, —CH2NHR13, —CH?O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.
    Type: Application
    Filed: February 26, 2014
    Publication date: August 18, 2016
    Inventors: Marc Labelle, Thomas Boesen, Qasim Khan, Ramkrishna Reddy Vakiti, Utpal Sharma, Ying Yang, Mukund Mehrotra, Neerja Saraswat, Farman Ullah